JP6629497B2 - がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット - Google Patents

がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット Download PDF

Info

Publication number
JP6629497B2
JP6629497B2 JP2013553044A JP2013553044A JP6629497B2 JP 6629497 B2 JP6629497 B2 JP 6629497B2 JP 2013553044 A JP2013553044 A JP 2013553044A JP 2013553044 A JP2013553044 A JP 2013553044A JP 6629497 B2 JP6629497 B2 JP 6629497B2
Authority
JP
Japan
Prior art keywords
interleukin
cells
cell
whole blood
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013553044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510517A (ja
Inventor
ミョン イ，ジェ
ミョン イ，ジェ
チョン ユン，ジュ
チョン ユン，ジュ
ウ パク，サン
ウ パク，サン
ソン キム，ジョン
ソン キム，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NKmax Co Ltd
Original Assignee
NKmax Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NKmax Co Ltd filed Critical NKmax Co Ltd
Publication of JP2014510517A publication Critical patent/JP2014510517A/ja
Application granted granted Critical
Publication of JP6629497B2 publication Critical patent/JP6629497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2013553044A 2011-02-14 2012-02-10 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット Active JP6629497B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0012983 2011-02-14
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
PCT/IB2012/000259 WO2012110878A2 (en) 2011-02-14 2012-02-10 Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017069908A Division JP6798922B2 (ja) 2011-02-14 2017-03-31 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット

Publications (2)

Publication Number Publication Date
JP2014510517A JP2014510517A (ja) 2014-05-01
JP6629497B2 true JP6629497B2 (ja) 2020-01-15

Family

ID=46672988

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013553044A Active JP6629497B2 (ja) 2011-02-14 2012-02-10 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
JP2017069908A Active JP6798922B2 (ja) 2011-02-14 2017-03-31 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
JP2019126244A Pending JP2019207242A (ja) 2011-02-14 2019-07-05 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
JP2021197948A Withdrawn JP2022043119A (ja) 2011-02-14 2021-12-06 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
JP2023076634A Active JP7660605B2 (ja) 2011-02-14 2023-05-08 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017069908A Active JP6798922B2 (ja) 2011-02-14 2017-03-31 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
JP2019126244A Pending JP2019207242A (ja) 2011-02-14 2019-07-05 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
JP2021197948A Withdrawn JP2022043119A (ja) 2011-02-14 2021-12-06 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
JP2023076634A Active JP7660605B2 (ja) 2011-02-14 2023-05-08 がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット

Country Status (20)

Country Link
US (2) US11442069B2 (cg-RX-API-DMAC7.html)
EP (1) EP2676139B1 (cg-RX-API-DMAC7.html)
JP (5) JP6629497B2 (cg-RX-API-DMAC7.html)
KR (3) KR20120093002A (cg-RX-API-DMAC7.html)
CN (1) CN103370622B (cg-RX-API-DMAC7.html)
AU (2) AU2012219184A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013020454B1 (cg-RX-API-DMAC7.html)
CA (1) CA2826053C (cg-RX-API-DMAC7.html)
CL (1) CL2013002361A1 (cg-RX-API-DMAC7.html)
DK (1) DK2676139T3 (cg-RX-API-DMAC7.html)
EA (1) EA038959B1 (cg-RX-API-DMAC7.html)
ES (1) ES2797549T3 (cg-RX-API-DMAC7.html)
IL (1) IL227952B (cg-RX-API-DMAC7.html)
MX (1) MX361731B (cg-RX-API-DMAC7.html)
MY (1) MY175351A (cg-RX-API-DMAC7.html)
RU (1) RU2635194C2 (cg-RX-API-DMAC7.html)
SG (1) SG192247A1 (cg-RX-API-DMAC7.html)
TW (2) TWI681191B (cg-RX-API-DMAC7.html)
UA (1) UA120697C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012110878A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
JP6549570B2 (ja) 2013-11-05 2019-07-24 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 膀胱癌バイオマーカー
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
MY199514A (en) 2018-02-01 2023-11-02 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
AU2020221310B2 (en) * 2019-02-14 2025-10-16 Research Institute At Nationwide Children's Hospital Use of a stimulating agent to assay immune cell potency
WO2021041399A1 (en) * 2019-08-29 2021-03-04 Board Of Regents, The University Of Texas System Cell cryopreservation medium
JP2022550743A (ja) * 2019-09-25 2022-12-05 リートー ラボラトリーズ カンパニー リミテッド 組換えインターロイキン－１５アナログ
JP2023505102A (ja) * 2019-11-29 2023-02-08 エヌケーマックス カンパニー リミテッド ナチュラルキラー細胞を製造する方法およびその組成物
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
WO2023111569A1 (en) * 2021-12-17 2023-06-22 University Of Kent Sequences and methods for production of recombinant biological molecules in vesicles
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
CN115855779A (zh) * 2023-01-18 2023-03-28 山东康华生物医疗科技股份有限公司 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89121A (pt) * 1987-12-04 1989-12-29 Du Pont Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
ES2167373T3 (es) * 1993-08-09 2002-05-16 Edward Baral Un metodo para la sensibilizacion de celulas cancerosas con respecto a la lisis mediada por celulas asesinas.
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP3995248B2 (ja) 2001-08-13 2007-10-24 準二郎 土山 エプスタインバーウイルス陰性のｎｋ細胞株
EP1451217A4 (en) * 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
EP1494712A4 (en) 2002-03-26 2006-06-14 Centocor Inc MULTIPLE SCLEROSIS RELATED PROTEINS, COMPOSITIONS, PROCESSES AND APPLICATIONS DERIVED FROM IMMUNOGLOBULIN
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
US7534585B2 (en) 2003-07-21 2009-05-19 Transgene S.A. Multifunctional cytokines
JP2007501618A (ja) 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法
MXPA06005104A (es) 2003-11-05 2007-01-25 Palingen Inc Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim.
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
KR100565764B1 (ko) * 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
EP1901766A2 (en) * 2005-04-08 2008-03-26 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
WO2008013975A2 (en) * 2006-07-28 2008-01-31 The Research Foundation Of State University Of New York Methods and kits for measurement of lymphocyte function
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
EP2048237A1 (en) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Also Published As

Publication number Publication date
EA038959B1 (ru) 2021-11-15
CN103370622A (zh) 2013-10-23
RU2635194C2 (ru) 2017-11-09
MX361731B (es) 2018-12-14
AU2012219184A1 (en) 2013-09-05
KR101341538B1 (ko) 2013-12-18
US20140017713A1 (en) 2014-01-16
CA2826053A1 (en) 2012-08-23
JP2017129597A (ja) 2017-07-27
CN103370622B (zh) 2018-02-13
ES2797549T3 (es) 2020-12-02
JP7660605B2 (ja) 2025-04-11
NZ614345A (en) 2015-09-25
DK2676139T3 (da) 2020-06-15
US20220229070A1 (en) 2022-07-21
JP6798922B2 (ja) 2020-12-09
BR112013020454B1 (pt) 2023-03-21
CL2013002361A1 (es) 2014-06-27
TWI681191B (zh) 2020-01-01
BR112013020454A8 (pt) 2022-11-29
AU2017202628A1 (en) 2017-05-11
WO2012110878A3 (en) 2013-01-31
EP2676139B1 (en) 2020-05-06
IL227952B (en) 2019-01-31
US11442069B2 (en) 2022-09-13
TW201741670A (zh) 2017-12-01
EA201391187A1 (ru) 2013-12-30
KR20120093002A (ko) 2012-08-22
NZ710432A (en) 2017-04-28
TW201245718A (en) 2012-11-16
KR20130032410A (ko) 2013-04-01
US12379384B2 (en) 2025-08-05
MX2013009380A (es) 2013-12-16
TWI668445B (zh) 2019-08-11
SG192247A1 (en) 2013-09-30
EP2676139A2 (en) 2013-12-25
KR101438573B1 (ko) 2014-09-12
BR112013020454A2 (pt) 2016-10-18
WO2012110878A2 (en) 2012-08-23
AU2017202628B2 (en) 2019-08-22
JP2023115006A (ja) 2023-08-18
IL227952A0 (en) 2013-09-30
UA120697C2 (uk) 2020-01-27
JP2014510517A (ja) 2014-05-01
JP2019207242A (ja) 2019-12-05
RU2013141487A (ru) 2015-03-27
JP2022043119A (ja) 2022-03-15
MY175351A (en) 2020-06-22
KR20130136012A (ko) 2013-12-11
EP2676139A4 (en) 2014-12-03
CA2826053C (en) 2021-05-25

Similar Documents

Publication Publication Date Title
JP7660605B2 (ja) がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット
CN109425743B (zh) 检测可溶性fam19a4蛋白的微球双抗体夹心检测方法和试剂盒
KR20140045409A (ko) 초기 류마티스성 관절염의 진단 방법
KR20140083986A (ko) 항wt1 항체의 측정 방법
US9945843B2 (en) Methods for identifying compounds that inhibit G protein-coupled receptor (GPR84) agonist-stimulated chemotaxis
HK1189273B (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
HK1189273A (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
NZ614345B2 (en) Method and use for measurement of nk cell activity
NZ710432B2 (en) Method and use for measurement of nk cell activity
JP6565099B2 (ja) 家族性地中海熱のバイオマーカー
JP2016035448A (ja) 難治性血管炎の病態を特定する新規なｍｐｏ−ａｎｃａ検査法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170403

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170530

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191205

R150 Certificate of patent or registration of utility model

Ref document number: 6629497

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250